Figure 2.

Relationship of the informed decision-making module with follow-up visits and with breast, colorectal, and prostate cancer screening.

PSA = prostate-specific antigen.

Note: Percentages of patients who received screening tests were derived from electronic health record data for a period of 3 months after completion of the decision module. Although the colorectal cancer screening rate appears low, this study included only the subset of practice patients overdue for that screening. On the basis of prior studies and practice quality program participation, about 70% of patients in the study practices have been screened for colorectal cancer.⁴⁶